Everything You Need to Know About Leqembi Maintenance and Medicare
After Leqembi removes amyloid plaques from the brain, treatment isn't over. The brain continues to produce beta-amyloid every day, and in Alzheimer's disease a small amount escapes the brain's natural clearance systems. Without continued treatment, these molecules can gradually accumulate again, forming toxic oligomers, protofibrils, and eventually new plaques. This article explains why maintenance therapy is essential after the initial 18 months of Leqembi, compares monthly IV infusions with the FDA-approved IQLIK® self-injection, and provides a practical guide to Medicare Part B and Part D coverage, specialty pharmacies, formularies, prior authorization, and out-of-pocket costs so you can make informed decisions about your long-term treatment options.
How Leqembi and Kisunla Fight Alzheimer's in Different Ways
A diagnosis of Alzheimer's no longer means there are no treatment options. Two FDA-approved drugs, Leqembi and Kisunla, can slow the disease for people diagnosed early, but they work differently. Understanding how beta-amyloid changes from harmless protein fragments into toxic oligomers, protofibrils, plaques, and eventually tau tangles can help patients and families make more informed treatment decisions.
Learn How Alzheimer’s Creeped Into My Brain
Alzheimer's doesn't begin with memory loss. It begins silently 20 to 30 years earlier as changes in beta-amyloid, toxic oligomers, inflammation, and tau gradually damage the brain. This article explains the modern science behind Alzheimer's in clear, understandable language and shows how new blood tests, biomarkers, and treatments like Leqembi are transforming diagnosis, and offering hope for the future.
Leqembi Does Much More Than Remove Plaque
Most people think Leqembi simply removes amyloid plaque. The science tells a much bigger story. Researchers now believe tiny beta-amyloid oligomers begin damaging synapses and disrupting the brain's glutamate-GABA balance years before plaques appear. Understanding how Leqembi targets these toxic proteins changed the way I think about Alzheimer's disease, and why early treatment matters.
Why People with Alzheimer's Forget the Right Word (and How to Find It Again)
Do you have to pause or just describe a word you can't quickly recall? For people living with Alzheimer's disease, word-finding problems are among the earliest and most frustrating symptoms. The encouraging news is that the word is often not gone. The brain may simply have difficulty finding the pathway to retrieve it. In this article, I explain the neuroscience behind word retrieval, why Alzheimer's disrupts these language networks, and how practical strategies based on neuroplasticity can help strengthen communication and restore confidence.
How Leqembi’s Multi-Target Strategy Fights Alzheimer’s
For decades, Alzheimer's treatments could do little more than ease symptoms while the disease continued its relentless attack on the brain. Leqembi represents a different approach. Rather than simply treating the consequences of Alzheimer's, it targets the disease itself by attaching to harmful beta-amyloid proteins at multiple stages of their development—from the smallest, most toxic clusters to fully formed plaques. By interrupting this destructive process early and continuing to remove existing amyloid, Leqembi gives the brain a better opportunity to protect neurons, preserve memory, and maintain the connections that define who we are. Understanding why this matters begins with understanding how Alzheimer's damages the brain.